TuHURA Biosciences (HURA) Competitors $2.95 -0.30 (-9.23%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$3.16 +0.21 (+7.12%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock HURA vs. SNDL, ZVRA, ARCT, SVRA, OPT, PVLA, SEPN, ARVN, BCYC, and MBXShould you be buying TuHURA Biosciences stock or one of its competitors? The main competitors of TuHURA Biosciences include SNDL (SNDL), Zevra Therapeutics (ZVRA), Arcturus Therapeutics (ARCT), Savara (SVRA), Opthea (OPT), Palvella Therapeutics (PVLA), Septerna (SEPN), Arvinas (ARVN), Bicycle Therapeutics (BCYC), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. TuHURA Biosciences vs. Its Competitors SNDL Zevra Therapeutics Arcturus Therapeutics Savara Opthea Palvella Therapeutics Septerna Arvinas Bicycle Therapeutics MBX Biosciences TuHURA Biosciences (NASDAQ:HURA) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends. Which has stronger earnings and valuation, HURA or SNDL? TuHURA Biosciences has higher earnings, but lower revenue than SNDL. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$21.68MN/AN/ASNDL$671.81M0.94-$69.18M-$0.27-8.89 Which has more risk & volatility, HURA or SNDL? TuHURA Biosciences has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, SNDL has a beta of 3.57, indicating that its stock price is 257% more volatile than the S&P 500. Do analysts rate HURA or SNDL? TuHURA Biosciences currently has a consensus price target of $12.67, suggesting a potential upside of 329.38%. SNDL has a consensus price target of $4.00, suggesting a potential upside of 66.67%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than SNDL.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40SNDL 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of HURA or SNDL? 0.6% of TuHURA Biosciences shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is HURA or SNDL more profitable? TuHURA Biosciences has a net margin of 0.00% compared to SNDL's net margin of -10.38%. SNDL's return on equity of -8.58% beat TuHURA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A -248.79% -150.83% SNDL -10.38%-8.58%-7.23% Does the media prefer HURA or SNDL? In the previous week, SNDL had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 2 mentions for SNDL and 1 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.34 beat SNDL's score of 0.20 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SNDL 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTuHURA Biosciences beats SNDL on 9 of the 14 factors compared between the two stocks. Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HURA vs. The Competition Export to ExcelMetricTuHURA BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.65M$3.12B$5.81B$9.74BDividend YieldN/A2.24%4.40%4.08%P/E RatioN/A20.6430.0825.84Price / SalesN/A339.63430.47102.66Price / CashN/A43.2325.7828.79Price / Book8.689.649.465.99Net Income-$21.68M-$54.08M$3.27B$265.29M7 Day Performance-1.67%5.58%3.65%4.07%1 Month Performance3.51%4.11%3.54%0.93%1 Year PerformanceN/A6.70%30.57%18.21% TuHURA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HURATuHURA Biosciences1.4576 of 5 stars$2.95-9.2%$12.67+329.4%N/A$162.65MN/A0.00N/ASNDLSNDL1.7006 of 5 stars$2.16+6.9%$4.00+85.2%+13.7%$530.81M$671.81M-8.002,516ZVRAZevra Therapeutics3.3839 of 5 stars$9.20-2.4%$23.71+157.8%+30.4%$529.35M$23.61M-43.8120ARCTArcturus Therapeutics2.5713 of 5 stars$17.91-8.1%$50.00+179.2%-19.5%$528.97M$152.31M-8.03180SVRASavara3.2526 of 5 stars$3.05+0.3%$6.17+102.2%-28.1%$525.42MN/A-6.1020OPTOpthea0.2249 of 5 stars$3.41+7.2%$1.33-60.9%+18.8%$524.84M$120K0.008Upcoming EarningsGap UpHigh Trading VolumePVLAPalvella Therapeutics2.9204 of 5 stars$49.55+4.8%$57.10+15.2%N/A$523.12M$42.81M-4.10N/ASEPNSepterna1.6931 of 5 stars$11.59-1.1%$26.75+130.8%N/A$522.54M$1.08M-1.15N/AARVNArvinas3.9991 of 5 stars$7.17+1.1%$19.76+175.6%-71.4%$520.53M$263.40M-7.10420Positive NewsBCYCBicycle Therapeutics3.2772 of 5 stars$7.54+1.3%$22.22+194.7%-68.2%$515.25M$35.28M-2.15240Positive NewsMBXMBX Biosciences1.9 of 5 stars$14.57-1.0%$37.63+158.2%N/A$489.47MN/A-3.2136 Related Companies and Tools Related Companies SNDL Competitors ZVRA Competitors ARCT Competitors SVRA Competitors OPT Competitors PVLA Competitors SEPN Competitors ARVN Competitors BCYC Competitors MBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HURA) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access